Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics

by rvvadmin | Jun 17, 2021 | 2021

TORONTO, June 17, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...

Revive To Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

by rvvadmin | Jun 14, 2021 | 2021

TORONTO, June 14, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced...

Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India

by rvvadmin | Jun 8, 2021 | 2021

TORONTO, June 08, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip

by rvvadmin | May 17, 2021 | 2021

TORONTO, May 17, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...

Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19

by rvvadmin | May 3, 2021 | 2021

TORONTO, May 03, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...

Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury

by rvvadmin | Apr 27, 2021 | 2021

TORONTO, April 27, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has...